Intravenous Immunoglobulin

Author:

Vaishampayan Sanjeev S.,Bhati Surendra Singh,Lachhiramani Radha R.,Shrivastava Shivank,Jain Prateek,Raghuwanshi Ajay Singh

Abstract

Background: Many a times while treating dermatoses conventional therapies are either contraindicated or not effective. Intravenous immunoglobulin (IVIG) is a good alternative available to tide over crises. Method: Over the last 15 years of my practice I have used IVIg in various severe or recalcitrant diseases (including TEN, autoimmune blistering disease, connective tissue disorders, chronic urticaria etc) which were either unresponsive to conventional modality of therapy or primary therapy could not be given because of co-morbidities. Result: IVIg a sterile, highly purified preparation containing more than 95% unmodified IgG, was first approved by FDA in 1981 for 6 diseases. As mentioned above in many circumstances we reached a situation when either conventional primary therapy was contraindicated or patients were not responding. IVIg came to our rescue in large number of conditions to tide over the crisis and also created the environment leading to conventional therapy becoming effective. Very few minor side effects like low grade fever and myalgia were observed in very few cases. No serious or severe side effects were seen, however, one has to be prepared for anaphylactic reaction which is a theoretical possibility. Conclusion: It can be said that IVIg though not a magic drug, is a very effective tool available in the armamentarium of Dermatologists to treat plethora of chronic and intractable dermatoses.

Publisher

Medknow

Reference17 articles.

1. Dermatological uses of high-dose intravenous immunoglobulin;Jolles;Arch Dermatol,1998

2. Intravenous immunoglobulin in dermatology;Dhar;Indian J Dermatol,2009

3. Corticosteroid sparing effects of IVIg therapy in patients with pemphigus vulgaris;Hopkins;Arch Dermatol,2002

4. Treatment of pyoderma gangrenosum with intravenous immunoglobulin;Cummins;Br J Dermatol,2007

5. The effectiveness of low-dose intravenous immunoglobulin in chronic urticaria;Kroiss;Acta Derm Venereol,2000

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3